



Date: 09th July, 2024

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400051
BSE Scrip Code: 543308

To,
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (E),
Mumbai- 400001
NSE Scrip Code: KIMS

To,
Krishna Institute of Medical Sciences Limited,
D.No.1-8-31/1,
Minister's Road, Secunderabad,
Telangana – 500003, India

Sub: Disclosures under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI SAST Regulations”) - Report to Stock Exchanges in respect of acquisition made in accordance with exemption provided for in Regulation 10(1)(d)(iii) of the SEBI SAST Regulations.

Dear Sir/Madam,

With reference to the captioned subject, please note that the Hon’ble National Company Law Tribunal (“NCLT”), Hyderabad Bench has approved the Scheme of Amalgamation of BVR Projects Private Limited (“Transferor Company 1”) and Bollineni Ramanaiah Memorial Hospitals Private Limited (“Transferor Company 2”) with Bluebridge Capital Private Limited (“Transferee Company”) vide its order dated 07th June, 2024 (filed with the Registrar of Companies, Hyderabad on 06th July, 2024 vide SRN AA9111814, AA9112178 and SRN AA9112739).

Further, Bollineni Ramanaiah Memorial Hospitals Private Limited holds 48,40,662 equity shares of Krishna Institute of Medical Sciences Limited (“Target Company”) amounting to 6.05% of the total shareholding of the Target Company. Pursuant to the approval of the Scheme of Amalgamation of BVR Projects Private Limited (“Transferor Company 1”) and Bollineni Ramanaiah Memorial Hospitals Private Limited (“Transferor Company 2”) with Bluebridge Capital Private Limited (“Transferee Company”) by the Hon’ble NCLT, all the assets and liabilities including the 48,40,662 equity shares amounting to 6.05% of the total shareholding of the Target Company held by Bollineni Ramanaiah Memorial Hospitals Private Limited shall stand transferred / merged into Bluebridge Capital Private Limited.

For Bluebridge Capital Private Limited

Survey no's 611, 612 & 613 mission compound Shamshabad post and mandalam. Rangareddi, Telangana, India 501218.

Email: BB@bluebridgecapital.in CIN: U65993TG2020PTC144611

Director



In this regard, please find enclosed herewith the report under regulation 10(6) of the SEBI SAST Regulations in respect of acquisition of shares of the Target Company pursuant to regulation 10(1)(d)(iii) of the SEBI SAST Regulations on account of amalgamation of BVR Projects Private Limited ("Transferor Company 1") and Bollineni Ramanaiah Memorial Hospitals Private Limited ("Transferor Company 2") with Bluebridge Capital Private Limited ("Transferee Company").

It is hereby informed that the total shareholding of the Promoter/ Promoter Group before and after the amalgamation shall remain the same and the name of Bollineni Ramanaiah Memorial Hospitals Private Limited shall stand substituted with Bluebridge Capital Private Limited.

The amalgamation is amongst the entities which are ultimately controlled by the same individuals / beneficial owners who hold the entire voting rights in the combined entity, before and after the implementation of the aforementioned Scheme of Amalgamation and the same fulfils the criteria for exemption under Regulation 10(1)(d)(iii) of the SEBI SAST Regulations.

We hereby request you to take the aforementioned information on records and disseminate the same on your respective websites.

Thanking You,

Yours Sincerely,

For Bluebridge Capital Private Limited



Subba Rao Veeravenkata Meka

Director (DIN: 07173955)

Place: Hyderabad

Date: 09th July, 2024



Format for Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Krishna Institute of Medical Sciences Limited
2.	Name of the acquirer(s)	Bluebridge Capital Private Limited
3.	Name of the stock exchange where shares of the TC are listed	1. BSE (formerly Bombay Stock Exchange) 2. National Stock Exchange
4.	Details of the transaction including rationale, if any, for the transfer/acquisition of shares.	The Hon'ble National Company Law Tribunal ("NCLT"), Hyderabad Bench vide its order dated 07th June, 2024 approved the Scheme of Amalgamation of BVR Projects Private Limited and Bollineni Ramanaiah Memorial Hospitals Private Limited with Bluebridge Capital Private Limited {CP (CAA) No. 68/230/HDB/2023} ("Scheme") filed with the Registrar of Companies, Hyderabad on 06th July, 2024 vide SRN AA9111814, AA9112178 and SRN AA9112739. Bollineni Ramanaiah Memorial Hospitals Private Limited holds 48,40,662 equity shares of Krishna Institute of Medical Sciences Limited ("Target Company") amounting to 6.05% of the total shareholding of the Target Company. Pursuant to the approval of the Scheme by the Hon'ble NCLT, all the assets and liabilities including the 48,40,662 equity shares amounting to 6.05% of the total shareholding of the Target Company held by Bollineni Ramanaiah Memorial Hospitals Private Limited shall stand transferred / merged into Bluebridge Capital Private Limited.

For Bluebridge Capital Private Limited

5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(d)(iii) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. In terms of the regulation 10(1)(d)(iii) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, acquisition pursuant to a scheme of arrangement not directly involving the target company as a transferor company or as a transferee company, or reconstruction not involving the target company's undertaking, including amalgamation, merger or demerger, pursuant to an order of a court or a tribunal, is exempted from the requirement of making an open offer under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Not Applicable	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
	a. Name of the transferor / seller	Not Applicable	Not Applicable
	b. Date of acquisition	Not Applicable	Not Applicable
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	Not Applicable	Not Applicable

For Bluebridge Capital Private Limited



	d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	Not Applicable		Not Applicable	
	e.	Price at which shares are proposed to be acquired / actually acquired	Not Applicable		Not Applicable	
8.	Shareholding details		Pre-Transaction		Post-Transaction	
			No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	A	Each Acquirer / Transferee (*) Bluebridge Capital Private Limited	Nil	Nil	48,40,662 equity shares	6.05%
	B	Each Seller / Transferor Bollineni Ramanaiah Memorial Hospitals Private Limited	48,40,662 equity shares	6.05%	Nil	Nil

Note:

- (*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

For **Bluebridge Capital Private Limited**



Subba Rao Veeravenkata Meka

Director (DIN: 07173955)

Place: Hyderabad

Date: 09th July, 2024

Survey no's 611, 612 & 613 mission compound Shamshabad post and mandalam. Rangareddi, Telangana, India 501218.

Email: BB@bluebridgecapital.in CIN: U65993TG2020PTC144611